Aytu BioPharma, Inc. (AYTU) Income Statement
AYTU FY2026 at a glance
Fiscal year ended June 30, 2026 · U.S. dollarsAYTU revenue and net income
Where AYTU's revenue goes
FY2026Each bar shows an amount and its share of revenue. AYTU kept −24.8% of revenue as net income.
AYTU profit margins
AYTU growth rates
to FY2026| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | −13.3% | −18.8% | −2.6% | +36.5% |
| Gross profit | −19.7% | −17.9% | +4.7% | +36.8% |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
AYTU quarterly EPS vs estimates
Aytu BioPharma beat the analyst EPS estimate in 7 of the last 8 quarters. Next report: November 12, 2026 (estimate $-0.10).
AYTU income statement
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $57.6M | $66.4M | $65.2M | $107.4M | $96.7M | $65.6M | $27.6M | $7.3M | $3.7M | $3.2M |
| Cost of revenue | $20.8M | $20.6M | $16.1M | $40.8M | $46.4M | $36.4M | $8.3M | $2.2M | $2.1M | $1.4M |
| Gross profit | $36.8M | $45.8M | $49.1M | $66.6M | $50.3M | $29.2M | $19.4M | $5.1M | $1.6M | $1.8M |
| Research & development | $0 | $1.3M | $2.8M | $4.1M | $12.7M | $5.6M | $1.7M | $589,072 | $167,595 | $1.3M |
| Sales, general & admin | $42.6M | $38.3M | $42.0M | $70.1M | $69.9M | $55.8M | $31.1M | $19.2M | $17.7M | $17.6M |
| Total operating expenses | $45.1M | $53.7M | $50.6M | $83.7M | $160.2M | $88.1M | $40.5M | $22.0M | $19.5M | $20.7M |
| Operating income | −$8.3M | −$7.8M | −$1.6M | −$17.1M | −$109.9M | −$58.9M | −$21.1M | −$16.8M | −$19.7M | −$20.1M |
| Interest income | — | — | — | — | — | — | — | $454,720 | $3.2M | $2.4M |
| Interest expense | $1.9M | $3.7M | $4.8M | $5.0M | $147.5M | $37.5M | $0 | $0 | $749,423 | $2.5M |
| Income before taxes | −$14.2M | −$13.7M | −$10.4M | −$17.1M | −$108.9M | −$58.0M | −$13.6M | −$27.1M | −$10.2M | −$22.5M |
| Income taxes | −$21,000 | $437,000 | $2.1M | −$57,000 | −$110,000 | $259,000 | −$9.9M | $20.0M | −$2.1M | $1.1M |
| Net income | −$14.3M | −$13.6M | −$15.8M | −$17.1M | −$108.8M | −$58.3M | −$13.6M | −$47.2M | −$10.2M | −$22.5M |
| EBITDA | −$4.4M | −$4.7M | $1.4M | −$3.3M | −$28.0M | −$29.0M | −$12.2M | −$14.1M | −$15.3M | −$15.6M |
| EPS (diluted) | −$0.78 | −$2.74 | −$2.86 | −$5.04 | −$60.84 | −$53.82 | −$96.20 | −$720.12 | −$11559.71 | −$197440.00 |
| Gross margin | 64.0% | 69.0% | 75.3% | 62.0% | 52.0% | 44.5% | 70.0% | 69.9% | 44.0% | 56.0% |
| Operating margin | −14.4% | −11.8% | −2.4% | −15.9% | −113.7% | −89.7% | −76.5% | −230.1% | −538.3% | −624.7% |
| Net margin | −24.8% | −20.4% | −24.3% | −15.9% | −112.5% | −88.8% | −49.3% | −644.3% | −278.4% | −698.7% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $16.1M | $12.4M | $15.2M | $13.9M | $15.1M | $18.5M | $16.2M | $16.6M | $18.0M | $14.0M | $18.7M | $17.8M |
| Cost of revenue | $4.4M | $5.6M | $6.1M | $4.7M | $4.9M | $5.6M | $5.4M | $4.6M | $6.1M | $3.7M | $4.1M | $4.8M |
| Gross profit | $11.7M | $6.8M | $9.1M | $9.2M | $10.3M | $12.8M | $10.8M | $12.0M | $11.9M | $10.4M | $14.6M | $13.0M |
| Research & development | $0 | $0 | $0 | $0 | $216,000 | $162,000 | $522,000 | $426,000 | $1.0M | $611,000 | $521,000 | $595,000 |
| Sales, general & admin | $10.4M | $10.9M | $11.1M | $10.2M | $8.5M | $9.3M | $9.7M | $10.8M | $11.1M | $10.2M | $10.0M | $12.4M |
| Total operating expenses | $12.5M | $10.9M | $11.1M | $10.7M | $17.9M | $10.4M | $12.5M | $12.9M | $15.6M | $12.0M | $11.5M | $13.9M |
| Operating income | −$777,000 | −$4.1M | −$2.0M | −$1.5M | −$7.6M | $2.4M | −$1.7M | −$930,000 | −$3.6M | −$1.6M | $3.1M | −$867,000 |
| Interest expense | $383,000 | $436,000 | $560,000 | $516,000 | $730,000 | $900,000 | $1.1M | $994,000 | $4.8M | $1.3M | $1.3M | $1.3M |
| Income before taxes | −$4,000 | −$5.6M | −$10.6M | $2.0M | −$19.4M | $3.8M | $382,000 | $1.5M | −$3.9M | −$1.8M | $1.4M | −$7.5M |
| Income taxes | −$11,000 | $10,000 | — | — | $437,000 | −$122,000 | −$283,000 | $405,000 | $695,000 | $521,000 | $780,000 | −$2.2M |
| Net income | −$15,000 | −$5.6M | −$10.6M | $2.0M | −$19.8M | $4.0M | $788,000 | $1.5M | −$4.6M | −$2.9M | −$220,000 | −$8.1M |
| EBITDA | $1.4M | −$4.1M | −$9.1M | $3.3M | −$17.4M | $6.0M | $2.6M | $3.9M | −$6.0M | $1.0M | $4.5M | −$4.3M |
| EPS (diluted) | −$0.05 | −$0.41 | −$0.23 | −$0.09 | −$2.93 | $0.21 | $0.13 | −$0.15 | −$0.82 | −$0.52 | −$0.04 | −$1.48 |
| Gross margin | 72.6% | 55.1% | 60.0% | 66.1% | 67.8% | 69.4% | 66.5% | 72.3% | 66.2% | 73.9% | 77.9% | 73.2% |
| Operating margin | −4.8% | −32.7% | −13.0% | −10.8% | −50.4% | 13.1% | −10.4% | −5.6% | −20.3% | −11.4% | 16.8% | −4.9% |
| Net margin | −0.1% | −45.3% | −69.8% | 14.1% | −130.9% | 21.6% | 4.9% | 8.9% | −25.7% | −20.6% | −1.2% | −45.6% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in AYTU's financial statements (latest annual report filed September 22, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
AYTU financial results
In fiscal year 2026 (ended June 30, 2026), Aytu BioPharma reported revenue of $57.6 million, down 13.3% from the year before. It had a net loss of $14.3 million, a net profit margin of −24.8%. Diluted earnings per share came to −$0.78. Over five years revenue grew at an average rate of −2.6% a year.
See the AYTU stock overview for the latest quote and news, or the AYTU chart for price history and technical indicators.
AYTU income statement FAQ
What is Aytu BioPharma's annual revenue?
Aytu BioPharma reported total revenue of $57.6 million for fiscal year 2026, which ended on June 30, 2026. That was down 13.3% from $66.4 million the previous year.
Is Aytu BioPharma profitable?
No. Aytu BioPharma reported a net loss of $14.3 million in fiscal 2026, a net profit margin of −24.8%; its operating margin was −14.4%.
What is Aytu BioPharma's gross margin?
Aytu BioPharma's gross margin was 64.0% in fiscal 2026: for every $100 of revenue, Aytu BioPharma kept $64 after the direct cost of its products and services.
How fast is Aytu BioPharma growing?
Revenue grew −2.6% a year on average over the last five fiscal years, from $65.6 million to $57.6 million.
What are Aytu BioPharma's earnings per share?
Aytu BioPharma earned $-0.78 per diluted share in fiscal 2026, compared with $-2.74 a year earlier.
When will Aytu BioPharma report its next earnings?
Aytu BioPharma is expected to report results for the quarter ending September 30, 2026 on November 12, 2026.
When does Aytu BioPharma's fiscal year end?
Aytu BioPharma's fiscal year ends in June. The latest annual report covers the year ended June 30, 2026 and was filed on September 22, 2026.